Proteasome inhibitors in cancer therapy /

Bibliographic Details
Other Authors:	Adams, Julian, 1954-
Format:	Book
Language:	English
Published:	Totowa, N.J. : Humana Press, [2004]
Series:	Cancer drug discovery and development.
Subjects:	Neoplasms > drug therapy. Clinical Trials as Topic. Drug Design. Drug Evaluation, Preclinical. Protease Inhibitors > therapeutic use.

Table of Contents:

Cancer drug development
Cancer drug development : challanges in a competitive market
Chemistry and cell biology of the proteasome
Introduction to the proteasome and its inhibitors : biochemistry and cell biology
Structures of the yeast proteasome core particle in complex with inhibitors
Natural product and synthetic proteasome inhibitors
Other proteasome inhibitors
The proteasome in cell-cycle regulation
Proteasome in cell-cycle regulation
Proteasome inhibition and apoptosis
The proteasome and the COMPARE algorithm
Rationale for proteasome inhibitors in cancer
The proteasome in cancer biology and therapy
Radiosensitivity and proteasome inhibition
Proteasome-dependent regulation of NF-kB activation : molecular targeting of chemotherapy resistance
Bortezomib with taxanes
Proteasome inhibitor therapy in a brain tumor model
Anthracyclines and bortezomib
TNF-related apoptosis-inducing ligand (TRAIL) : combination with proteasome inhibition for anticancer therapy?
Rationale for combining the proteasome inhibitor bortezomib with cisplatin
The effects of the HIV-1 protease inhibitor ritonavir on proteasome activity and antigen presentation
Function(s) of the ubiquitin-proteasome system in retrovirus budding
Clinical trials
Preclinical development of bortezomib (VELCADE) : rationale for clinical studies
Phase I trials : bortezomib alone and in combination with standard chemotherapies
Clinical molecular diagnostics for proteasome inhibitors in cancer therapy
Phase II trials of bortezomib for the treatment of multiple myeloma